It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potential…
Just after Genzyme announced that it signed a confidentiality agreement with Sanofi Aventis to allow the French drugmaker to examine its books, leaks about the potential deal started pouring out. The numbers and details vary, s…
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the pa…
Diabetes is a growing global scourge, but for Big Pharma it’s more of a lifesaver — and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes cou…
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the…